17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
February 2026 in “European Urology”
29 citations
,
April 2019 in “BMJ. British medical journal” Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
Finasteride, a medication, is being re-evaluated for its effects and uses.
August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” 5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
17 citations
,
December 2018 in “The World Journal of Men s Health” Long-term use of dutasteride can cause permanent erectile dysfunction in rats.
2 citations
,
September 2012 in “Asian Journal of Pharmaceutical Analysis” A method was created in 2012 to accurately and precisely measure tamsulosin and finasteride in medicine using second derivative spectrophotometric method.
January 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” A simple, precise method was created for estimating Tamsulosin and Finasteride in medicine using common lab solvents, showing good precision and stability.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
21 citations
,
January 2017 in “Dermatology Online Journal” Finasteride and dutasteride can cause sexual problems like impotence and low libido.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
May 2024 in “News Digital Object Group”
42 citations
,
December 2007 in “American Journal of Psychiatry” Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
October 2009 in “Nature Reviews Urology” Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.